is tirzepatide a peptide hormone Tirzepatide, New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review Tirzepatide | GLP-1R and GIPR

5) Blood System : Purpura and platelet dysfunction were observed very rarely after administration of this drug

Importantly, these benefits are independent of glucose-lowering effects, establishing them as "additional benefits" in diabetes management [35, 36]

Simoni, M

Phase 4: Therapeutic dose (Weeks 13-16) Dose: 8 mg or 9 mg once weekly What to expect: Strong appetite suppression Significant ongoing weight loss Possible temporary GI flare during escalation Many reach 10-15% weight loss by this phase Tips: This is where most people stabilize 8 mg may be sufficient for manyhigher isn't always better Continue lifestyle optimization Regular check-ins with healthcare provider Phase 5: Maximum dose (Week 17+) Dose: 12 mg once weekly (if tolerated and needed) What to expect: Maximum therapeutic effect Continued weight loss (averaging 20%+ by 48 weeks in trials) GI side effects may be manageable or may persist Some achieve 25-30%+ weight loss Tips: Not everyone needs to reach 12 mg Lower doses may provide sufficient results Balance efficacy with tolerability Maintenance may involve dose reduction For general peptide dosing principles, see our peptide dosage calculator guide

2024 Jun;44(3):324-332

Improved Glycemic Control in T2D Tirzepatide's FDA approval for type 2 diabetes was granted following completion of five phase-3 trials in the SURPASS global clinical development program